全文获取类型
收费全文 | 16479篇 |
免费 | 1264篇 |
国内免费 | 318篇 |
专业分类
耳鼻咽喉 | 95篇 |
儿科学 | 376篇 |
妇产科学 | 159篇 |
基础医学 | 709篇 |
口腔科学 | 20篇 |
临床医学 | 3352篇 |
内科学 | 5112篇 |
皮肤病学 | 52篇 |
神经病学 | 331篇 |
特种医学 | 435篇 |
外国民族医学 | 1篇 |
外科学 | 2428篇 |
综合类 | 2008篇 |
预防医学 | 923篇 |
眼科学 | 59篇 |
药学 | 1521篇 |
11篇 | |
中国医学 | 219篇 |
肿瘤学 | 250篇 |
出版年
2023年 | 293篇 |
2022年 | 245篇 |
2021年 | 590篇 |
2020年 | 655篇 |
2019年 | 578篇 |
2018年 | 526篇 |
2017年 | 597篇 |
2016年 | 551篇 |
2015年 | 634篇 |
2014年 | 1197篇 |
2013年 | 1252篇 |
2012年 | 1161篇 |
2011年 | 1159篇 |
2010年 | 934篇 |
2009年 | 836篇 |
2008年 | 709篇 |
2007年 | 757篇 |
2006年 | 660篇 |
2005年 | 566篇 |
2004年 | 512篇 |
2003年 | 449篇 |
2002年 | 423篇 |
2001年 | 342篇 |
2000年 | 290篇 |
1999年 | 262篇 |
1998年 | 224篇 |
1997年 | 217篇 |
1996年 | 155篇 |
1995年 | 151篇 |
1994年 | 152篇 |
1993年 | 146篇 |
1992年 | 106篇 |
1991年 | 84篇 |
1990年 | 55篇 |
1989年 | 74篇 |
1988年 | 72篇 |
1987年 | 58篇 |
1986年 | 45篇 |
1985年 | 58篇 |
1984年 | 43篇 |
1983年 | 31篇 |
1982年 | 42篇 |
1981年 | 40篇 |
1980年 | 34篇 |
1979年 | 20篇 |
1978年 | 22篇 |
1977年 | 13篇 |
1976年 | 14篇 |
1975年 | 7篇 |
1973年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
1.
2.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
3.
目的:探讨连续性血液净化治疗患儿静脉留置导管感染风险因素,据此构建风险预测体系,并检验其实际应用效果,以期为临床预防护理提供依据。方法:选取医院2018年4月—2020年4月收治的400例连续性血液净化治疗患儿,按两组基础资料具有匹配性原则将其分为构建组300例、验证组100例,统计构建组中静脉留置导管感染患儿例数,通过单因素分析、多因素Logistic回归分析筛选静脉留置导管感染的独立危险因素,据此构建风险预测体系,并检验其在验证组中的应用效果。结果:经统计得到,构建组中静脉留置导管感染患儿共66例,感染发生率为22.00%;单因素分析得到,连续性血液净化治疗患儿静脉留置导管感染风险因素有穿刺部位、导管留置时间、插管次数、血流速度、血红蛋白、遵医依从性、抗生素使用时间、操作人员手卫生(P<0.05);多因素Logistic回归分析得到,连续性血液净化治疗患儿静脉留置导管感染独立风险因素有股静脉置管、导管留置时间>7 d、血流速度>180 mL/min、血红蛋白<100 g/L、遵医依从性差、抗生素使用时间>7 d(P<0.05);构建得到连续性血液净化治疗患儿静脉留置导管感染风险预测体系为P=1/[1+e^(-(-1.935+1.635×股静脉置管+1.740×导管留置时间>7 d+1.725×血流速度>180 mL/min+2.241×血红蛋白<100 g/L+2.089×遵医依从性差+1.331×抗生素使用时间>7 d))],ROC曲线分析显示,曲线下面积AUC=0.881,灵敏度为86.67%,特异性为97.14%,准确率为94.00%。结论:连续性血液净化治疗患儿静脉留置导管感染风险大,且风险因素复杂,研究构建的静脉留置导管感染风险预测体系灵敏度高、特异性强,评估准确率高。 相似文献
4.
目的 探讨瞬时脉冲足底静脉泵预防全髋/膝关节置换术后深静脉血栓形成(DVT)的效果,为临床医护人员选择最优的机械预防方式提供参考依据。方法 选取2019年11月至2020年8月在我院关节外科拟行全髋/膝关节置换术的病人210例,随机分为观察组(105例)和对照组(105例);术后,观察组和对照组分别使用瞬时脉冲足底静脉泵和间歇性充气加压装置预防DVT。观察比较两组病人术后DVT的发生率、术后D-二聚体、C-反应蛋白、白细胞介素-6和患肢肿胀情况,住院时间和使用机械设备预防DVT的舒适度。结果 术后2周,观察组DVT总发生率为6.67%,对照组为9.52%,两组比较,差异无统计学意义(P>0.05);观察组病人机械设备使用的舒适度高于对照组,差异有统计学意义(P<0.05)。结论 瞬时脉冲足底静脉泵可有效预防全髋/膝关节置换术后DVT,且舒适度高于间歇充气加压装置,预防DVT的时间成本低,值得临床推广。 相似文献
5.
Klemen Dovc MD Michelle Van Name MD Barbara Jenko Bizjan PhD Ewa Rusak MD Claudia Piona MD Gul Yesiltepe-Mutlu MD Rosaline Mentink MD Giulio Frontino MD Maddalena Macedoni MD Sofia Helena Ferreira MD Joana Serra-Caetano MD Júlia Galhardo MD Julie Pelicand MD Francesca Silvestri MD Jennifer Sherr MD Agata Chobot MD Torben Biester MD for the ISPAD JENIOUS Group 《Diabetes, obesity & metabolism》2022,24(3):564-569
6.
《Journal of emergency nursing》2022,48(4):484-491
BackgroundCalcium chloride is commonly used in emergency departments in the treatment of a variety of emergencies. Historically, administration via central venous catheters has been preferred owing to its high osmolarity and vesicant properties. Although preferred, central access may not always be available in time-sensitive, emergent situations leading to many instances of peripheral administration. The objective of this analysis was to evaluate the charted safety of peripheral venous administration of 10% calcium chloride.MethodsA single-center retrospective chart review was performed in patients who received 10% calcium chloride in the adult emergency department evaluating for the incidence of infusion-related adverse events. Patients were excluded if they were less than 18 years of age or had a lack of catheter documentation during 10% calcium chloride administration or if the 10% calcium chloride was documented as given through a central venous catheter.ResultsA total of 72 administrations were evaluated. Patients were predominantly male (67%), with a median age of 55 years and body mass index of 29.2. The primary outcome demonstrated that 4 infusion-related adverse events occurred (6%) with grade 1 (n = 1) and grade 0 (n = 3) documented incidence of infusion-related adverse events. None of the documented incidence of infusion-related adverse events resulted in permanent tissue injury, and all patients had conservative management.DiscussionThis study demonstrated that administration of 10% calcium chloride via peripheral venous catheters may be feasible and seemed to carry a low incidence of documented complications. Further prospective studies are needed to confirm study observations. 相似文献
7.
8.
9.
Toshihiro Nakamura MD Kunihiko Kiuchi MD FHRS Koji Fukuzawa MD Mitsuru Takami MD Yoshiaki Watanabe MD Yu Izawa MD Hideya Suehiro MD Tomomi Akita MD Makoto Takemoto MD Jun Sakai MD Atsusuke Yatomi MD Yusuke Sonoda MD Hiroyuki Takahara MD Kazutaka Nakasone MD Kyoko Yamamoto MD Noriyuki Negi RT Atsushi Kono MD Takashi Ashihara MD PhD Ken-ichi Hirata MD PhD 《Journal of cardiovascular electrophysiology》2021,32(4):1005-1013
10.